In this Issue
- Phase 2 Study of Oral Ketamine for Depression Lauded by Media and Sponsor, Yet Closer Look Reveals Underwhelming Results
- UN World Drug Report Comments on ‘Developments Around Psychedelics’
- Another Californian Psychedelic Policy Reform Bill Bites the Dust
- First Look at Beckley’s IV Psilocin
- Other Stories (inc. stories from Compass Pathways, MindBio, Apex Labs, Relmada Therapeutics, MindMed, Otsuka, Lundbeck, INVI MindHealth, Numinus Wellness, Lykos Therapeutics, Healing Realty Trust, MedBright AI, and others).
***
Sign-in or join Pα+ to continue reading…
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Already a member? Log In
✓ Regular Bulletins covering key topics and trends in the psychedelics space
✓ Regular articles and deep dives across psychedelic research, policy and business
✓ Interviews with insiders
✓ Monthly interactive database and commentary on psychedelic patents
✓ Quick-take analysis of major developments
✓ A Library of primers and explainers
✓ Access to our full back catalogue